Earnings Releases·Nov 13, 2026, 4:35 PM ET

Calidi Biotherapeutics — Third Quarter 2026 Earnings Summary

Reported a net loss of $3.6 million for Q3 2026, a significant improvement from $10.8 million in Q3 2025, driven by a $5.7 million non-cash warrant charge in the prior year; net loss per share was $(1.47) versus $(35.25) previously.
Executed a restructuring plan on November 6, 2026, expected to save $3 million annually, while G&A expenses fell 39% year-over-year to $1.6 million; cash and cash equivalents decreased to $3.9 million as of September 30, 2026.
Advanced lead candidate CLD-401 through IND-enabling studies for metastatic non-small cell lung cancer and head and neck cancer, with preclinical data showing complete tumor eradication in 80% of EMT6 breast cancer models.
Plans to dose the first patient in the second half of 2027 and raised $1.2 million via an at-the-market registered direct offering closed on September 18, 2026.